title: [Experimental study of targeting therapy of breast cancer with 131I-labeled epidermal growth factor].
abstract: OBJECTIVE
  To investigate the effectiveness of (131)I-epidermal growth factor (EGF) on the proliferation of a heterologous graft in nude mice bearing human breast infiltrating duct carcinoma.
  
  
  METHODS
  EGF/HAS was labeled with (131)I by chloramines-T method. Human breast cancer xenografts with positive EGFR expression were established in nude mice. The nude mice were injected with normal saline, Epirubicin Hydrochloride, (131)I-EGF, (131)I-HAS, (131)I intravenously and (131)I-EGF intratumoral administration respectively. The tumor growth inhibition rate was determined by measurement of tumor volume. Different examinations were carried out.
  
  
  RESULTS
  There was remarkable significant difference of tumor volumes at 26th day among (131)I-EGF trial groups, (131)I, (131)I-HAS, and the negative control group. The tumor growth inhibition rate of (131)I-EGF trial groups was 82.0%, 80.7% respectively. Compared with the negative control group, the (131)I-EGF trial groups remarkably suppressed the growth of tumor (P < 0.05). Irreversible destruction of tissues in (131)I-EGF groups was observed under light and electron microscope. There was no evidence of hepatotoxicity, renal toxicity and myelotoxicity in nude mice bearing human breast cancer given (131)I-EGF over a 4-wk observation period.
  
  
  CONCLUSIONS
  (131)I-EGF has obvious antitumor effects on a heterologous graft in nude mice bearing human breast infiltrating duct carcinoma, with little obvious side effects.
authors.affiliation: Department of Breast Surgery, Mianyang Central Hospital, Mianyang 621000, China. myxuweiyun@hotmail.com
authors.forename: Wei-yun
authors.initials: WY
authors.lastname: Xu
authors.forename: Yun-chun
authors.initials: YC
authors.lastname: Li
authors.forename: Sheng
authors.initials: S
authors.lastname: He
authors.forename: Yang-bing
authors.initials: YB
authors.lastname: Zhao
authors.forename: Hong-jiang
authors.initials: HJ
authors.lastname: Li
authors.forename: Xian-yun
authors.initials: XY
authors.lastname: Yao
mesh_terms: D000818:Animals; D004815:Epidermal Growth Factor / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000378:metabolism / Q000532:radiotherapy*; D051379:Mice; D008819:Mice, Nude; D016499:Radioimmunotherapy; D023041:Xenograft Model Antitumor Assays
chemical_list: D007457:Iodine Radioisotopes; D004815:Epidermal Growth Factor; D066246:ErbB Receptors